Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alza's OROS delivery system

Executive Summary

Firm announced on June 19 that its oral osmotic technology will be applied to Glaxo's Ventolin (albuterol) bronchodilator and to Pfizer's Minipress (prazosin) antihypertensive, under joint development agreements with the two pharmaceutical mfrs. Glaxo and Pfizer will make and market the controlled release formulations under a royalty-bearing license from Alza. Pfizer has a similar agreement for an OROS version of the calcium channel blocker Procardia (nifedipine).
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS010326

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel